Key Highlights

  • Kromek Group shares rose 4.94% with no fresh announcement, following a run of positive operational news.
  • A third milestone payment of $2.5m was received under the Siemens Healthineers agreement in August 2026, taking total payments to $32.5m.
  • Half-year Revenue to 31 October 2025 jumped to £15.0m from £3.7m, with adjusted EBITDA swinging to £6.0m from a £2.3m loss.
  • Non-executive chairman Rakesh Sharma bought 129,413 shares in early August 2026, a signal of board-level confidence.
  • Full-year revenue guidance of about £27.2m was reiterated, with audited results due in September.

A quiet mover on a thinly traded AIM share

Shares in Kromek Group (LSE:KMK) edged higher, adding close to 5% in a session that left the AIM-quoted radiation and bio-detection specialist back among the day's more actively watched small caps. For a company whose stock trades in single-digit pence and whose order flow can be lumpy, a move of that size says as much about limited Liquidity as it does about any decisive shift in sentiment.

There was no single company announcement on the day that obviously accounts for the rise. The latest price action follows a period in which Kromek has delivered a run of operational news, from a milestone payment under its landmark medical-imaging deal to insider buying by its chairman, with the group's audited full-year figures now only weeks away. Investors appear to be reassessing a Business reshaped over two years around two higher-margin technology franchises.

Kromek, based in Sedgefield in the North East of England, designs detectors based on cadmium zinc telluride (CZT) semiconductors. Its technology sits inside next-generation medical scanners and in equipment used to detect chemical, biological, radiological and nuclear (CBRN) threats. It is a niche, deep-technology story that has long promised more than it has delivered in hard cash, which is precisely why the recent numbers matter.

Recent developments keep the story in view

The most consequential recent update came on 6 August 2026, when Kromek confirmed it had delivered the third milestone under its enablement agreement with Siemens Healthineers and received a $2.5m payment. That takes total cash collected under the arrangement to $32.5m, with a final $5.0m instalment expected by April 2029. The agreement, first struck in early 2025, effectively licenses Kromek's imaging technology to one of the world's largest medical-equipment makers and has been the single biggest driver of the group's recent revenue step-up.

Days earlier, on 3 August, the company disclosed that non-executive chairman Rakesh Sharma had bought 129,413 shares at 7.57p. Director purchases are never a guarantee of anything, but at a micro-cap they are often read as a signal of confidence at board level. The accompanying grant of Options to management was a reminder that incentives here are tightly bound to the imaging deal's progress.

In its full-year trading update on 12 May, Kromek said it expected revenue of about £27.2m for the year to 30 April 2026, in line with market expectations, and pointed to £8.8m of new orders secured in the second half, a significant proportion of which was delivered before the year end. Audited results are scheduled for September.

The financial and operational picture

The scale of Kromek's transformation is clearest in its half-year figures. For the six months to 31 October 2025, revenue jumped to £15.0m from just £3.7m a year earlier. The Advanced Imaging division contributed £10.8m, flattered by the Siemens contribution but still up around 41% on an underlying basis, while CBRN Detection more than doubled to £4.3m from £2.0m. Gross Margin widened sharply to 71.7% from 56.9%, reflecting the higher weighting towards licensing and technology income.

That mix drove a swing to adjusted EBITDA of £6.0m, against a £2.3m loss a year earlier, and a pre-tax profit of £3.1m versus a £5.7m loss. For a company that has reported losses for much of its listed life, the move into profit is the crux of the Investment case.

The Balance Sheet remains the area demanding the most scrutiny. Cash stood at just £1.2m at the half-year, down from £1.7m at the April 2025 year end, supported by a £6.0m revolving Credit Facility (£1.0m drawn) and a £0.5m asset-finance line. Milestone receipts such as the recent $2.5m help, but the group is still working capital-hungry, and the timing of large orders and payments can leave period-end cash looking thin. On the order side, the first half brought a £1.7m award under the UK Government's Radiological Nuclear Detection framework and a £250,000 Ministry of Defence contract for biological-agent detection development, alongside orders across Europe, the US, Japan, Canada and Australasia.

What could drive the shares next

The clearest near-term catalyst is the audited full-year report due in September, which will confirm whether the £27.2m revenue guidance and the implied return to full-year profitability have been met, and will reveal the closing cash position that the trading update left undisclosed. Any commentary on the FY27 order book and on the pace of the Siemens roll-out could move the shares either way.

Beyond that, investors will be watching for further CBRN contract wins. Government spending on nuclear-security and biological-threat detection has been a structural tailwind, and Kromek's framework positions in the UK and US give it a route to repeat orders, even if procurement timelines are slow. Broadening its detector technology beyond a single anchor customer would also strengthen the case that the recent profitability is durable rather than a one-off.

Risks investors should watch

The most obvious risk is concentration. A large slice of recent revenue and margin has flowed from the Siemens agreement, and while further milestone and licence income is contracted, the underlying commercial imaging opportunity still has to be proven at scale. Lumpy, milestone-driven revenue can flatter one period and leave the next looking soft.

Liquidity and funding are the second concern. With cash of around £1.2m at the half-year and reliance on a modest credit facility, Kromek has limited buffer if a major order slips or working-capital needs spike, which keeps the possibility of future fundraising and dilution on the table. The shares are also thinly traded, so price swings can be exaggerated on modest volume.

Finally, much of Kromek's addressable market is tied to government and defence budgets and to the capital-spending cycles of large medical-equipment makers. Procurement delays, as management has flagged in the CBRN division, can push revenue between periods and make forecasting difficult.

Investor takeaway

Kromek has done the hard part of turning a long-promising technology portfolio into revenue growth, expanding margins and a genuine swing into profit, and the market is beginning to acknowledge that. The modest share-price gain looks less like a reaction to a fresh catalyst and more like continued repricing of a business that now has real Earnings to point to. The September results, the closing cash figure and the shape of the FY27 order book are the milestones worth marking in the diary. For now, the question is whether Kromek can convert its niche detector Franchise into consistent, self-funding profitability, and that remains a story to monitor rather than one that is settled.